Post-earnings recap
Reported
Wed, Feb 25, 2026
EPS actual
$1.60
EPS est.
$0.12
EPS surprise
+1211.48%
1-day move
+1.55%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
ACADIA PHARMACEUTICAL's strong EPS performance significantly exceeded expectations, which contributed to a 1.55% increase in stock price. The lack of revenue data and guidance may leave some investors cautious, but the substantial EPS beat suggests underlying strength in their operations. Investors will be looking for more clarity in future reports.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.60 | N/A | +1211.48% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a positive outlook regarding their earnings performance. However, they did not provide specific guidance for future revenue.
Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.
They emphasized their commitment to long-term growth and innovation.